Cycle-length evidence
N-Acetyl Epithalon Amidate cycle length: what human studies ran
Not approved — research use only
Short answer: there is no established N-Acetyl Epithalon Amidate cycle length, and we found no human studies that report one.
Treatment and follow-up in human studies
No human study durations are recorded.
What has not been tested
- On-and-off schedules or breaks between courses.
- Repeated courses and long-term exposure beyond the periods listed.
- N-Acetyl Epithalon Amidate combined with other compounds, unless a study above says so.
Frequently asked questions
Is there an established N-Acetyl Epithalon Amidate cycle length?
No. We found no human studies that report a treatment duration for N-Acetyl Epithalon Amidate.
What is the longest human study of N-Acetyl Epithalon Amidate?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
References
- Epitalon and Epithalamin: A Narrative Review of Mechanistic, Preclinical, and Clinical Evidence Int J Mol Sci. 2026
- Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties Int J Mol Sci. 2025
- PubChem compound name search for "N-Acetyl Epithalon Amidate" and variants returned no CID (searched 22 October 2026) PubChem. 2026
- Epitalon (CID 219042): molecular formula C14H22N4O9, molecular weight 390.35; a name search for "Epithalamin" also resolves to this record PubChem. 2026
- PubMed searches returning zero records: "N-acetyl epithalon amidate", "epithalon amidate", "acetylated epitalon", AEDG AND amide (searched 22 October 2026) PubMed. 2026
- Therapeutic peptides in gerontology: mechanisms and applications for healthy aging Front Aging. 2026
- DailyMed drug name search returned no labels for epitalon (searched 22 October 2026) DailyMed. 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
- Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa Neuro Endocrinol Lett. 2002
- Systemic and Topical Geroprotective Rejuvenation Assessed by START/REST Aging Clocks (NCT07888595), early phase 1, enrolling by invitation ClinicalTrials.gov. 2026
- LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma Cell Death Dis. 2026
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions J Am Acad Orthop Surg Glob Res Rev. 2026
- World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026